BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 9215615)

  • 21. Expression of genes involved in nucleotide excision repair and sensitivity to cisplatin and melphalan in human cancer cell lines.
    Damia G; Guidi G; D'Incalci M
    Eur J Cancer; 1998 Oct; 34(11):1783-8. PubMed ID: 9893669
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sensitivity of CHO mutant cell lines with specific defects in nucleotide excision repair to different anti-cancer agents.
    Damia G; Imperatori L; Stefanini M; D'Incalci M
    Int J Cancer; 1996 Jun; 66(6):779-83. PubMed ID: 8647649
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combined cytotoxic effects of tumor necrosis factor-alpha with various cytotoxic agents in tumor cell lines that are drug resistant due to mutated p53.
    Sleijfer S; Le TK; de Jong S; Timmer-Bosscha H; Withoff S; Mulder NH
    J Immunother; 1999 Jan; 22(1):48-53. PubMed ID: 9924699
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Correlation of chemosensitivity to anticancer drugs and telomere length, telomerase activity and telomerase RNA expression in human ovarian cancer cells.
    Kiyozuka Y; Yamamoto D; Yang J; Uemura Y; Senzaki H; Adachi S; Tsubura A
    Anticancer Res; 2000; 20(1A):203-12. PubMed ID: 10769656
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Enhancing alkylating agent resistance through ERCC2 gene transfection in human glioma cell line.
    Chen Z; Zhang J; Mohr G
    Chin Med J (Engl); 2003 Aug; 116(8):1171-4. PubMed ID: 12935404
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cell survival in four ovarian carcinoma xenografts following in vitro exposure to melphalan, cisplatin and cis-diammine-1,1-cyclobutane dicarboxylate platinum II (CBDCA,JM8).
    Jones AC; Wilson PA; Steel GG
    Cancer Chemother Pharmacol; 1984; 13(2):109-13. PubMed ID: 6380788
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An inverse switch in DNA base excision and strand break repair contributes to melphalan resistance in multiple myeloma cells.
    Sousa MM; Zub KA; Aas PA; Hanssen-Bauer A; Demirovic A; Sarno A; Tian E; Liabakk NB; Slupphaug G
    PLoS One; 2013; 8(2):e55493. PubMed ID: 23405159
    [TBL] [Abstract][Full Text] [Related]  

  • 28. hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents.
    Brown R; Hirst GL; Gallagher WM; McIlwrath AJ; Margison GP; van der Zee AG; Anthoney DA
    Oncogene; 1997 Jul; 15(1):45-52. PubMed ID: 9233776
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Augmentation of adriamycin, melphalan, and cisplatin cytotoxicity in drug-resistant and -sensitive human ovarian carcinoma cell lines by buthionine sulfoximine mediated glutathione depletion.
    Hamilton TC; Winker MA; Louie KG; Batist G; Behrens BC; Tsuruo T; Grotzinger KR; McKoy WM; Young RC; Ozols RF
    Biochem Pharmacol; 1985 Jul; 34(14):2583-6. PubMed ID: 4040369
    [No Abstract]   [Full Text] [Related]  

  • 30. In vitro evidence for homologous recombinational repair in resistance to melphalan.
    Wang ZM; Chen ZP; Xu ZY; Christodoulopoulos G; Bello V; Mohr G; Aloyz R; Panasci LC
    J Natl Cancer Inst; 2001 Oct; 93(19):1473-8. PubMed ID: 11584063
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hypersensitivity to DNA cross-linking agents associated with up-regulation of glucose-regulated stress protein GRP78.
    Chatterjee S; Hirota H; Belfi CA; Berger SJ; Berger NA
    Cancer Res; 1997 Nov; 57(22):5112-6. PubMed ID: 9371511
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Potentiation of cisplatin cytotoxicity by lonidamine in primary cultures of human ovarian cancer.
    Orlandi L; Zaffaroni N; Gornati D; Veneroni S; Silvestrini R
    Anticancer Res; 1994; 14(3A):1161-4. PubMed ID: 8074467
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems.
    Perego P; Giarola M; Righetti SC; Supino R; Caserini C; Delia D; Pierotti MA; Miyashita T; Reed JC; Zunino F
    Cancer Res; 1996 Feb; 56(3):556-62. PubMed ID: 8564971
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Establishment and characterization of an in vitro model of acquired resistance to cisplatin in a human testicular nonseminomatous germ cell line.
    Kelland LR; Mistry P; Abel G; Freidlos F; Loh SY; Roberts JJ; Harrap KR
    Cancer Res; 1992 Apr; 52(7):1710-6. PubMed ID: 1312897
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Elevated DNA polymerase alpha, DNA polymerase beta, and DNA topoisomerase II in a melphalan-resistant rhabdomyosarcoma xenograft that is cross-resistant to nitrosoureas and topotecan.
    Friedman HS; Dolan ME; Kaufmann SH; Colvin OM; Griffith OW; Moschel RC; Schold SC; Bigner DD; Ali-Osman F
    Cancer Res; 1994 Jul; 54(13):3487-93. PubMed ID: 8012971
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines.
    Selvakumaran M; Pisarcik DA; Bao R; Yeung AT; Hamilton TC
    Cancer Res; 2003 Mar; 63(6):1311-6. PubMed ID: 12649192
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of reproducible low mass SELDI protein profiles specific to cisplatin resistance in human ovarian cancer cells.
    Britten RA; Hardy C; Vlahou A; Gregory B; Giri PS; Drake R
    Oncol Rep; 2005 Nov; 14(5):1323-30. PubMed ID: 16211304
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Selective potentiation of platinum drug cytotoxicity in cisplatin-sensitive and -resistant human ovarian carcinoma cell lines by amphotericin B.
    Sharp SY; Mistry P; Valenti MR; Bryant AP; Kelland LR
    Cancer Chemother Pharmacol; 1994; 35(2):137-43. PubMed ID: 7987990
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of DNA-repair-enzyme modulators on cytotoxicity of L-phenylalanine mustard and cis-diamminedichloroplatinum (II) in mammary carcinoma cells resistant to alkylating drugs.
    Alaoui-Jamali M; Loubaba BB; Robyn S; Tapiero H; Batist G
    Cancer Chemother Pharmacol; 1994; 34(2):153-8. PubMed ID: 8194166
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lactacystin enhances cisplatin sensitivity in resistant human ovarian cancer cell lines via inhibition of DNA repair and ERCC-1 expression.
    Li QQ; Yunmbam MK; Zhong X; Yu JJ; Mimnaugh EG; Neckers L; Reed E
    Cell Mol Biol (Noisy-le-grand); 2001; 47 Online Pub():OL61-72. PubMed ID: 11936875
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.